Tcr2 Therapeutics Executives
Tcr2 Therapeutics employs about 58 people. The company is managed by 10 executives with a total tenure of roughly 136 years, averaging almost 13.0 years of service per executive, having 5.8 employees per reported executive. Discussion of Tcr2 Therapeutics' management performance can provide insight into the enterprise performance.
Tcr2 |
Tcr2 Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3473) % which means that it has lost $0.3473 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9146) %, meaning that it created substantial loss on money invested by shareholders. Tcr2 Therapeutics' management efficiency ratios could be used to measure how well Tcr2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Tcr2 Therapeutics Workforce Comparison
Tcr2 Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,775. Tcr2 Therapeutics holds roughly 58.0 in number of employees claiming about 3% of equities under Health Care industry.
Tcr2 Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tcr2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tcr2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tcr2 Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mpm Sunstates Fund Lp over a year ago Acquisition or disposition of Tcr2 Therapeutics securities by Mpm Sunstates Fund Lp | ||
Peter Olagunju over a year ago Disposition of 24092 shares by Peter Olagunju of Tcr2 Therapeutics subject to Rule 16b-3 | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 50000 shares of Tcr2 Therapeutics | ||
Mpm Asset Management Llc over a year ago Exercise of in-the-money or at-the-money derivative position by Mpm Asset Management Llc of 135508 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 38765 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 57073 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Tcr2 Therapeutics exotic insider transaction detected |
Tcr2 Therapeutics Notable Stakeholders
A Tcr2 Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tcr2 Therapeutics often face trade-offs trying to please all of them. Tcr2 Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tcr2 Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Angela Justice | Chief Officer | Profile | |
| Patrick Baeuerle | Founder Board | Profile | |
| Richard Roomberg | VP Controller | Profile | |
| Dr MBA | CEO Pres | Profile | |
| Margaret JD | Head Sec | Profile | |
| Rosemary Harrison | Chief Officer | Profile | |
| Peter Olagunju | Chief Officer | Profile | |
| Alfonso MD | Chief Officer | Profile | |
| Carl Mauch | Sr Communications | Profile | |
| Eric CPA | Chief Officer | Profile |
Tcr2 Therapeutics Workforce Analysis
Traditionally, organizations such as Tcr2 Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tcr2 Therapeutics within its industry.Tcr2 Therapeutics Manpower Efficiency
Return on Tcr2 Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.6M | |
| Net Loss Per Executive | 15.2M | |
| Working Capital Per Employee | 2M | |
| Working Capital Per Executive | 11.4M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |